ICAD logo

iCAD (ICAD) Stock

Profile

Sector:

Healthcare

Country:

United States

IPO:

13 December 1984

Indexes:

Not included

Description:

iCAD is a technology company that develops advanced imaging and cancer detection solutions. They create software and tools to help healthcare professionals identify and diagnose diseases, particularly cancer, more accurately and efficiently. Their innovations aim to improve patient outcomes and support medical decision-making.

Events Calendar

Earnings

Next earnings date:

Mar 12, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

Mar 12, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Aug 16, 2012

Analyst ratings

Recent major analysts updates

19 July '23 Lake Street
Buy
13 Apr '23 JMP Securities
Outperform
04 Apr '23 Oppenheimer
Outperform
29 Mar '23 Lake Street
Buy
29 Mar '23 BTIG
Buy
01 Sept '22 JMP Securities
Market Outperform
11 Aug '22 Lake Street
Buy
24 June '22 BTIG
Buy
18 Jan '22 Guggenheim
Neutral
05 Jan '22 Oppenheimer
Outperform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024
iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024
iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024
ICAD
globenewswire.com26 November 2024

ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025 ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025

iCAD, Inc. (ICAD) Q3 2024 Earnings Call Transcript
iCAD, Inc. (ICAD) Q3 2024 Earnings Call Transcript
iCAD, Inc. (ICAD) Q3 2024 Earnings Call Transcript
ICAD
seekingalpha.com13 November 2024

iCAD, Inc. (NASDAQ:ICAD ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Rosalyn Christian - Investor Relations Dana Brown - President, Chief Executive Officer and Chairman Eric Lonnqvist - Chief Financial Officer Conference Call Participants Per Ostlund - Craig-Hallam Capital Yale Jen - Laidlaw & Company Operator Greetings. Welcome to the iCAD Incorporated Third Quarter 2024 Earnings Call.

iCAD to Attend 15th Annual Craig-Hallum Alpha Select Conference
iCAD to Attend 15th Annual Craig-Hallum Alpha Select Conference
iCAD to Attend 15th Annual Craig-Hallum Alpha Select Conference
ICAD
globenewswire.com06 November 2024

NASHUA, N.H., Nov. 06, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today announced that Dana Brown, Chief Executive Officer, and Eric Lonnqvist, Chief Financial Officer, will attend the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 19, 2024 at the Sheraton New York Times Square Hotel in New York City, New York. Management will be available for one-on-one meetings throughout the day. To request a meeting with iCAD, investors should contact their Craig-Hallum representative.

iCAD to Participate in the LD Micro Main Event XVII
iCAD to Participate in the LD Micro Main Event XVII
iCAD to Participate in the LD Micro Main Event XVII
ICAD
newsfilecorp.com16 October 2024

Nashua, New Hampshire--(Newsfile Corp. - October 16, 2024) - iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, announced today that management is participating in the LD Micro Main Event XVII on October 29-30, at the Luxe Sunset Boulevard Hotel, California. CEO Dana Brown will deliver a company presentation at 10:30 a.m.

iCAD Reports Financial Results for Second Quarter Ended June 30, 2024
iCAD Reports Financial Results for Second Quarter Ended June 30, 2024
iCAD Reports Financial Results for Second Quarter Ended June 30, 2024
ICAD
globenewswire.com13 August 2024

NASHUA, N.H., Aug. 13, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and six months ended June 30, 2024.

iCAD and Windsong Radiology Announce Strategic Commercial Agreement to Implement AI-Powered Mammography
iCAD and Windsong Radiology Announce Strategic Commercial Agreement to Implement AI-Powered Mammography
iCAD and Windsong Radiology Announce Strategic Commercial Agreement to Implement AI-Powered Mammography
ICAD
globenewswire.com29 July 2024

Windsong Radiology to Champion First Wave of ProFound AI Breast Health Suite Expansion Windsong Radiology to Champion First Wave of ProFound AI Breast Health Suite Expansion

iCAD to Participate in the MedInvest MedTech, AI & Digital Health Conference
iCAD to Participate in the MedInvest MedTech, AI & Digital Health Conference
iCAD to Participate in the MedInvest MedTech, AI & Digital Health Conference
ICAD
globenewswire.com04 June 2024

NASHUA, N.H., June 04, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, announced today the Company will present at the MedInvest MedTech, AI & Digital Healthcare Conference on June 11-12, 2024 in San Francisco, CA. Dana Brown, Chief Executive Officer, and Eric Lonnqvist, Chief Financial Officer, of iCAD, Inc., will participate in one-on-one meetings with investors at the event.

iCAD, Inc. (ICAD) Q4 2023 Earnings Call Transcript
iCAD, Inc. (ICAD) Q4 2023 Earnings Call Transcript
iCAD, Inc. (ICAD) Q4 2023 Earnings Call Transcript
ICAD
Seeking Alpha12 March 2024

iCAD, Inc. (ICAD) Q4 2023 Earnings Call Transcript

iCAD to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
iCAD to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
iCAD to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
ICAD
GlobeNewsWire27 February 2024

NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the Company will release financial results for the fourth quarter and full year 2023 financials after the market close, and host a conference call at 4:30 PM Eastern Time on Tuesday, March 12, 2024.

Discover Future Growth Stocks: 3 Penny Stocks Poised for Massive Returns
Discover Future Growth Stocks: 3 Penny Stocks Poised for Massive Returns
Discover Future Growth Stocks: 3 Penny Stocks Poised for Massive Returns
ICAD
InvestorPlace22 November 2023

Penny stocks are usually small-cap stocks, and small-cap stocks typically tend to perform the best during the early stages of the business cycle when the economy is recovering and growing fairly rapidly. Multi-billionaire investor Ken Fisher has indicated that we are in the early stages of the business cycle, and I agree with him.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the primary business of iCAD?
  • What is the ticker symbol for iCAD?
  • Does iCAD pay dividends?
  • What sector is iCAD in?
  • What industry is iCAD in?
  • What country is iCAD based in?
  • When did iCAD go public?
  • Is iCAD in the S&P 500?
  • Is iCAD in the NASDAQ 100?
  • Is iCAD in the Dow Jones?
  • When was iCAD's last earnings report?
  • When does iCAD report earnings?
  • Should I buy iCAD stock now?

What is the primary business of iCAD?

iCAD is a technology company that develops advanced imaging and cancer detection solutions. They create software and tools to help healthcare professionals identify and diagnose diseases, particularly cancer, more accurately and efficiently. Their innovations aim to improve patient outcomes and support medical decision-making.

What is the ticker symbol for iCAD?

The ticker symbol for iCAD is NASDAQ:ICAD

Does iCAD pay dividends?

No, iCAD does not pay dividends

What sector is iCAD in?

iCAD is in the Healthcare sector

What industry is iCAD in?

iCAD is in the Medical Devices industry

What country is iCAD based in?

iCAD is headquartered in United States

When did iCAD go public?

iCAD's initial public offering (IPO) was on 13 December 1984

Is iCAD in the S&P 500?

No, iCAD is not included in the S&P 500 index

Is iCAD in the NASDAQ 100?

No, iCAD is not included in the NASDAQ 100 index

Is iCAD in the Dow Jones?

No, iCAD is not included in the Dow Jones index

When was iCAD's last earnings report?

iCAD's most recent earnings report was on 13 November 2024

When does iCAD report earnings?

The next expected earnings date for iCAD is 12 March 2025

Should I buy iCAD stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions